Tucatinib vs Zanidatamab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HER2-Positive Breast Cancer
Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline
Tucatinib
Marketed by Pfizer and partners
NCT03975647 · Phase 3 · active, not recruiting
This was a randomized, quadruple-masked, placebo-controlled trial of 466 patients, with progression-free survival as the primary endpoint. The primary comparison reached statistical significance in favor of tucatinib (hazard ratio 0.759, p=0.0163).
Next expected readout: December 2026 · NCT06016387 (registry estimate)
Reported efficacy
Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Up to approximately 3 years): HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. (met)
Result source: NCT05132582
Zanidatamab
Marketed by Jazz Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07102381 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HER2-Positive Breast Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Zanidatamab: no structured comparison results are available for HER2-Positive Breast Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tucatinib
show 7 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Available safety results
Tucatinib
| Dropout rate | 34.6% NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more resultn/a: no completion milestone NCT02614794 · Phase 2 · combination |
|---|---|
| Discontinued due to AEs | — NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more result— NCT02614794 · Phase 2 · combination |
| Serious AEs | 30.3% NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more result30.7% NCT02614794 · Phase 2 · combination |
| Most frequent reported AEs | nausea 65.4% (placebo 48.5%) diarrhoea 56.7% (placebo 26.6%) fatigue 48.9% (placebo 36.5%) NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more resultdiarrhoea 81.7% (placebo 53.8%) palmar-plantar erythrodysaesthesia syndrome 65.6% (placebo 53.3%) nausea 60.1% (placebo 44.2%) NCT02614794 · Phase 2 · combination |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tucatinib's landscape · Zanidatamab's landscape